Friedlaender A, Metro G, Signorelli D, Gili A, Economopoulou P, Roila F, et al. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab. AO [Internet]. 2020 Sep. 1 [cited 2024 Nov. 21];59(9):1058-63. Available from: https://medicaljournalssweden.se/actaoncologica/article/view/24363